Cognitive Rehabilitation for Post-COVID Syndrome

AE
JH
Overseen ByJuliana H Earwood, OTD, OTR/L
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Missouri-Columbia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to assist individuals experiencing cognitive difficulties after COVID-19. It involves an online program called CO-OP (Cognitive Orientation to daily Occupational Performance), designed to enhance daily activities and quality of life. Participants will be divided into two groups: one will engage in the CO-OP program, while the other will not receive active treatment. Suitable candidates for this trial have ongoing memory or concentration issues that began after a COVID-19 infection and seek to improve their daily task performance. As an unphased trial, this study provides a unique opportunity for participants to potentially enhance their daily lives through innovative treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.

What prior data suggests that CO-OP Procedures are safe for individuals with post-COVID syndrome?

A previous study found the CO-OP (Cognitive Orientation to daily Occupational Performance) method to be both helpful and well-received. It improved participants' performance in daily tasks and their satisfaction with those tasks, while also aiding mood and anxiety. However, the studies reviewed did not provide specific safety information about using CO-OP for post-COVID syndrome, leaving no direct evidence of harmful effects from CO-OP itself.

Generally, methods like CO-OP are non-invasive, meaning they don't involve surgery or entering the body. They focus on improving thinking and planning skills through practice and support. These treatments are usually easy for participants to handle. If CO-OP had major safety issues, researchers likely wouldn't use it in studies. So, even without detailed safety data, the nature of the treatment suggests it is safe for most people.12345

Why are researchers excited about this trial?

Researchers are excited about the Cognitive Orientation to daily Occupational Performance (CO-OP) approach for Post-COVID Syndrome because it offers a unique, non-pharmacological method to address cognitive rehabilitation. Unlike standard treatments that might focus on medication or general cognitive exercises, CO-OP is a tailored strategy that helps individuals develop personalized skills to improve their daily functioning. This method is delivered remotely, making it accessible and convenient for participants, especially those who may still be experiencing mobility issues or prefer at-home care. By focusing on practical, goal-oriented tasks, CO-OP has the potential to provide significant, tangible benefits in daily life activities for those recovering from the cognitive impacts of COVID-19.

What evidence suggests that CO-OP Procedures could be effective for post-COVID syndrome?

Research has shown that the CO-OP (Cognitive Orientation to daily Occupational Performance) approach, which participants in this trial may receive, can enhance thinking skills in individuals with post-COVID syndrome. A similar method, cognitive remediation therapy, has effectively improved skills such as clear speech and task planning. Participants in programs like CO-OP have reported better cognitive abilities and improved daily performance. Studies also suggest that rehabilitation strategies can help manage long COVID symptoms, including mental and physical health issues. This evidence indicates that CO-OP could benefit those experiencing cognitive difficulties after COVID-19.12367

Who Is on the Research Team?

AE

Anna E Boone, PhD, OTR/L

Principal Investigator

University of Missouri Occupational Therapy

Are You a Good Fit for This Trial?

This trial is for individuals who have had COVID-19 and are struggling with cognitive issues at least 6 weeks after infection. Participants should be able to set personal goals, speak English fluently, give informed consent electronically, and have a past diagnosis of COVID-19. People with severe depression, untreated sleep apnea, prior cancer treatment, serious neurological or psychiatric conditions, or signs of dementia are not eligible.

Inclusion Criteria

I can give my consent electronically after understanding the study.
I have set personal activity goals with the COPM.
You have been diagnosed with COVID-19 before.
See 1 more

Exclusion Criteria

I have been diagnosed with a severe neurological or psychiatric condition.
I have had treatment for cancer before.
I have been diagnosed with dementia based on my MoCA score.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the CO-OP intervention remotely via Zoom, with one session per week over the course of 10 weeks

10 weeks
10 sessions (remote)

Control

Inactive control group receives one session per week over the course of 10 weeks, delivered remotely via Zoom

10 weeks
10 sessions (remote)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments conducted at the end of the study

2 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • CO-OP Procedures
  • Inactive Control Group
Trial Overview The study tests if CO-OP (Cognitive Orientation to daily Occupational Performance) delivered remotely can help improve everyday activity performance, cognition and quality of life in people with Post-COVID Syndrome compared to an inactive control group.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Inactive Control GroupExperimental Treatment1 Intervention
Group II: Cognitive Orientation to daily Occupational Performance (CO-OP)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Missouri-Columbia

Lead Sponsor

Trials
387
Recruited
629,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

Trials
2,103
Recruited
2,760,000+

Published Research Related to This Trial

A consensus conference involving 50 experts established clinical guidance for cognitive rehabilitation in military and civilian populations with persistent cognitive symptoms following mild traumatic brain injury, focusing on treatments effective three or more months post-injury.
The conference identified specific effective services within cognitive rehabilitation and emphasized the importance of assessment, intervention, and outcome measurement in developing treatment programs for cognitive impairment.
Cognitive rehabilitation for military personnel with mild traumatic brain injury and chronic post-concussional disorder: Results of April 2009 consensus conference.Helmick, K.[2018]
The CO-OP approach significantly improved rehabilitation clinicians' knowledge and self-efficacy in implementing cognitive strategies for stroke rehabilitation, as evidenced by positive changes in multiple-choice question scores and self-efficacy assessments after a 2-day workshop and 4 months of support.
After the intervention, there was a notable increase in the use of CO-OP strategies in practice, with 20% of medical records showing evidence of CO-OP use post-intervention, indicating a shift towards more client-centered goal setting in rehabilitation.
Implementing a function-based cognitive strategy intervention within inter-professional stroke rehabilitation teams: Changes in provider knowledge, self-efficacy and practice.McEwen, SE., Donald, M., Jutzi, K., et al.[2023]
Occupational therapists can enhance their role in cognitive rehabilitation by focusing on compensatory strategy training, which aligns with their expertise and history.
By increasing their involvement in research and transdisciplinary organizations, occupational therapists can lead advancements in cognitive rehabilitation, ultimately improving daily performance for individuals recovering from brain injuries.
Cognitive rehabilitation: advancing the stature of occupational therapy.Radomski, MV.[2019]

Citations

Cognitive Rehabilitation in Post-COVID-19 SyndromeCO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified ...
Interventions for the management of long covid (post-covid ...Conclusion. Moderate certainty evidence suggests that CBT and physical and mental health rehabilitation probably improve symptoms of long covid.
Cognitive Rehabilitation for Post-COVID SyndromeCognitive remediation therapy, which is similar to CO-OP Procedures, has shown effectiveness in improving cognitive functions like verbal fluency and executive ...
Outpatient group therapy for post-COVID patientsThe aim of this study was to develop a low-threshold group therapy concept for patients with PCS and to test its feasibility in face-to-face and online format.
Cognitive Orientation to daily Occupational Performance ...Design: Sixteen community residents ≥3 months post-COVID-19 infection with mild cognitive impairment and dysfunction in instrumental activities of daily living ...
Cognitive Orientation to daily Occupational Performance ...CO-OP was perceived as acceptable and beneficial in enhancing occupational performance, satisfaction and managing mood and anxiety symptoms.
A Framework for Addressing Clients' Functional Cognitive ...When working with people with COVID-19 long-haul syndrome, occupational therapy practitioners should stay focused on supporting clients' goals, ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security